Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE: 301211)
Health Care · Pharmaceuticals · CN
CN¥12.47
+2.38% today · -4.0% 1Y
Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE: 301211) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $774.64M and employs 952 people.
Over the last twelve months the share price has lost 4.0%, trading between 9.01 and 16.95.
Tweenvest scores Hubei Biocause Heilen Pharmaceutical Co., Ltd. across four factors: quality 66/100, value 39/100, growth 0/100, dividend 30/100. Its strongest factor is quality.
301211 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $774.64M
- Revenue (TTM)
- $66.55M
- P/E
- 155.88
- EPS
- 0.08
- Dividend yield
- 0.48%
- Beta (5Y)
- 0.51
- 52-week high
- CN¥16.95
- 52-week low
- CN¥9.01
- Avg volume (3M)
- —
- Shares outstanding
- 417.60M
- Employees
- 952
- Next earnings
- —
About Hubei Biocause Heilen Pharmaceutical Co., Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. is a Chinese enterprise with diverse operations spanning the pharmaceutical, chemical, and new energy fuel sectors. Within its pharmaceutical segment, the company manufactures active pharmaceutical ingredients (APIs), various intermediates, and finished drug formulations. Furthermore, its chemical offerings include industrial products such as dimethyl ether gas and chloropropionyl chloride. The firm is headquartered in Jingmen, China.
- Founded
- 1995
- Listed since
- Dec 22, 2021
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.75 | +0.19% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.56 | +0.66% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.